ArticleParasites & vectors2026
RNAi targeting ABCB1-like efflux transporters improves miticide efficacy in resistant Varroa mites.
Article in Parasites & vectors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe ectoparasitic mite Varroa destructor is the gravest threat to managed honeybees, and its control relies on a limited number of chemical miticides. Among these, amitraz is widely used because of its strong efficacy against mites and relatively low toxicity to bees. However, increasing resistance to amitraz in Varroa populations threatens its long-term effectiveness. While mutations in the mite's β2 octopamine receptor are strongly associated with amitraz resistance, additional mechanisms influencing toxicant uptake and efflux are believed to also contribute. ATP-binding cassette (ABC) transporters, including ABCB1/P-glycoproteins, are well-established mediators of xenobiotic efflux and pesticide tolerance across arthropods, making them promising targets for silencing via RNA interference (RNAi) to combat miticide resistance.
methodsWe cloned a full-length Varroa ABCB1-like transporter (VdABCB1) and synthesized dsRNAs targeting its coding sequence. Adult mites were treated with dsRNA prior to amitraz exposure in laboratory bioassays. Mite survival was analyzed longitudinally, and resistance-associated β2 octopamine receptor genotypes were determined. Varroa transcriptomic responses to dsRNA were assessed by RNA sequencing. Honeybee safety was evaluated in cage assays following chronic oral dsRNA exposure, including conservative tests co-administered with a known ABC transporter substrate.
resultsMites exposed to ABCB1 dsRNA showed greater amitraz-induced mortality than those treated with non-specific dsRNA. This effect was observed across multiple trials and amitraz concentrations. Transcriptomic analyses of mites revealed a significant knockdown of ABCB1-like transcripts following RNAi treatment. Chronic dietary exposure to ABCB1 dsRNA did not impact honeybee survival. Toxicity assays with ABCB1 dsRNA on its own or together with acetamiprid (ABC transporter substrate) as a high-risk interaction control showed minimal adverse effects on bees.
conclusionsRNAi suppression of Varroa ABCB1-like transporters increased amitraz mortality in resistant mites, identifying transporter-mediated efflux as a modifiable component of amitraz resistance. These findings demonstrate that targeted disruption of detoxification pathways can enhance miticide efficacy while minimizing off-target effects in bees. RNAi-based synergists therefore represent a selective resistance management strategy that could extend the effective lifespan of amitraz and other miticides relied on by the beekeeping industry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.